Mycobacterium tuberculosis
"Mycobacterium tuberculosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation.
| Descriptor ID |
D009169
|
| MeSH Number(s) |
B03.510.024.049.525.500.702 B03.510.460.400.410.552.552.702
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mycobacterium tuberculosis".
Below are MeSH descriptors whose meaning is more specific than "Mycobacterium tuberculosis".
This graph shows the total number of publications written about "Mycobacterium tuberculosis" by people in this website by year, and whether "Mycobacterium tuberculosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 3 | 4 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2008 | 4 | 3 | 7 |
| 2009 | 1 | 0 | 1 |
| 2010 | 5 | 1 | 6 |
| 2011 | 6 | 4 | 10 |
| 2012 | 6 | 6 | 12 |
| 2013 | 9 | 1 | 10 |
| 2014 | 9 | 3 | 12 |
| 2015 | 9 | 4 | 13 |
| 2016 | 6 | 5 | 11 |
| 2017 | 8 | 2 | 10 |
| 2018 | 12 | 3 | 15 |
| 2019 | 8 | 4 | 12 |
| 2020 | 11 | 1 | 12 |
| 2021 | 17 | 2 | 19 |
| 2022 | 7 | 0 | 7 |
| 2023 | 12 | 0 | 12 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mycobacterium tuberculosis" by people in Profiles.
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice. Elife. 2024 Apr 19; 13.
-
Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy study. Lancet Microbe. 2024 Jun; 5(6):e520-e528.
-
The performance of tongue swabs for detection of pulmonary tuberculosis. Front Cell Infect Microbiol. 2023; 13:1186191.
-
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing. PLoS One. 2023; 18(8):e0290496.
-
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study. Clin Infect Dis. 2023 08 14; 77(3):453-459.
-
SMA-TB: study protocol for the phase 2b randomized double-blind, placebo-controlled trial to estimate the potential efficacy and safety of two repurposed drugs, acetylsalicylic acid and ibuprofen, for use as adjunct therapy added to, and compared with, the standard WHO recommended TB regimen. Trials. 2023 Jun 28; 24(1):435.
-
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis. Lancet Infect Dis. 2023 07; 23(7):778-780.
-
Yield of Facility-based Targeted Universal Testing for Tuberculosis With Xpert and Mycobacterial Culture in High-Risk Groups Attending Primary Care Facilities in South Africa. Clin Infect Dis. 2023 05 03; 76(9):1594-1603.